When a clinical trial misses its primary endpoint or displays highly anomalous data, millions of dollars and years of development hang in the balance. The immediate corporate reaction is often catastrophic. However, a deep dive into historical regulatory metrics reveals a critical truth: many trial failures are not caused by a flawed molecule or device, but by uncontrolled technical noise, site-level protocol drift, or structural data pipeline errors.

As a senior professional, your leadership team will ask one definitive question: Is the product failing, or is the data wrong?To answer this, standard operational metrics are useless. You need a rigorous, forensic approach to data interrogation.

Join us for this intensive, technical briefing: Technical Rescue Strategies: Root Cause Evaluation of Failed Endpoints and Anomalous Data. Learn how to deploy advanced retrospective analysis protocols to isolate systemic noise from true clinical signals and build a scientifically defensible case for regulatory negotiation.

The line between a failed program and a salvageable asset comes down to data forensics. This webinar drops the high-level generalizations and focuses entirely on the technical mechanics of trial rescue.

When anomalous data compromises an endpoint, arbitrary data adjustments will trigger immediate regulatory rejection for “data fishing.” This session provides a step-by-step masterclass on how to execute a compliant, risk-hedged Root Cause Evaluation under ICH E6(R2/R3) guidelines.

The speaker will demonstrate how to centrally audit trial datasets, isolate “bad actor” or non-compliant study sites, and mathematically evaluate the impact of baseline covariate imbalances. Ultimately, you will learn how to translate these technical findings into an FDA Briefing Book that justifies protocol amendments, sample-size re-estimations, or modified endpoint criteria—protecting both your budget and your clinical asset.

Topics to be Covered

This webinar will cover following topics:

Forensic Data Diagnostics & Site Auditing

• Deploying Centralized Statistical Monitoring (CSM) to detect anomalous clustering, variance inflation, and digitized digit-preference at specific clinical sites.
• Isolating site-level operational drift, improper blinding execution, and measurement protocol failures.
• Auditing the Electronic Case Report Form (eCRF) architecture to identify systemic data-entry bugs vs. actual clinical outcomes.

Executing a Defensible Retrospective Analysis

• Establishing the strict regulatory boundary between unscientific “data dredging” and a validated, compliant retrospective analysis.
• Applying mathematical models to technically justify sensitivity analyses with and without anomalous site data.
• Technical frameworks for identifying and adjusting for unstratified baseline characteristics that skew primary endpoint results.

Regulatory Packaging & FDA Negotiation Strategy

• Structuring Clinical Overview and Clinical Study Reports within the eCTD package to transparently present anomalous data findings.
• Strategies for presenting retrospective forensics to the FDA to secure agreements on adaptive protocol amendments.
• Risk-hedging methodologies to preserve investor confidence while meeting rigid regulatory scrutiny.

Why You Should Attend

• Protect Millions in R&D Capital: Learn how to prevent the premature abandonment of a viable therapeutic candidate by identifying fixable data and operational errors.
• Master Regulatory Defense: Gain a clear framework for presenting retrospective data findings to global regulatory bodies without triggering penalties for post-hoc bias.
• Acquire Actionable Forensics: Walk away with concrete statistical and data-mapping techniques that you can immediately apply to current noisy datasets.
• Shift from Reactive to Proactive: Learn how to embed central statistical monitoring into your active trials to catch anomalies before database lock.

Who Will Benefit

This technical briefing is specifically architected for middle and senior-level drug, biologic, and medical device professionals responsible for trial integrity, risk management, and regulatory defense:

• Directors & VPs of Clinical Operations: Looking for technical oversight frameworks to audit CRO data transfers and manage site-level non-compliance.
• Heads of Biostatistics & Data Managers: Needing defensible mathematical strategies for handling outliers, missing data, and sensitivity testing.
• Regulatory Affairs Strategists: Responsible for compiling FDA Briefing Books and leading End-of-Phase meetings following anomalous trial results.
• QA/QC Directors & Clinical Auditors: Seeking to upgrade their root cause evaluation protocols for data integrity issues.